Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study

Autor: M Buchfelder, D Weigel, M Droste, K Mann, B Saller, K Brübach, G K Stalla, M Bidlingmaier, C J Strasburger

Publikováno v: European journal of endocrinology. 161(1)

In treatment-resistant patients with acromegaly, pharmacotherapy with pegvisomant (Somavert) is a highly effective option. However, safety concerns have been raised related to a potential increase in tumor size during long-term pegvisomant treatment.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b4df21c261e1d7ba7cad9af3c163346
https://pubmed.ncbi.nlm.nih.gov/19411302

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study.

Autor: Buchfelder M; Department of Neurosurgery, University of Erlangen-Nürnberg, Schwabachanlage 6, 91054 Erlangen, Germany. michael.buchfelder@uk-erlangen.de, Weigel D, Droste M, Mann K, Saller B, Brübach K, Stalla GK, Bidlingmaier M, Strasburger CJ

Publikováno v: European journal of endocrinology [Eur J Endocrinol] 2009 Jul; Vol. 161 (1), pp. 27-35. Date of Electronic Publication: 2009 May 01.